StoneX Group’s Enveric Biosciences ENVB Stock Holding History

StoneX Group’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$41.1K	Buy	27,986 +16,172	+137%	+$23.4K	﹤0.01%	1641
2026 Q2	$21.9K	Buy	+11,814	New	+$28.4K	﹤0.01%	1304

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

StoneX Group's ENVB Position: Q3 2026 in Review

StoneX Group increased its Enveric Biosciences (ENVB) stake by 137% in Q3 2026, buying an estimated $23.4K and bringing the position to 27,986 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

StoneX Group first reported a position in ENVB in Q2 2026 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold ENVB as of Q3 2026.

StoneX Group held 27,986 shares of Enveric Biosciences worth $41.1K as of Q3 2026.
StoneX Group bought 16,172 Enveric Biosciences shares in Q3 2026, an estimated $23.4K.
Enveric Biosciences made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1641 holding.
StoneX Group first reported a position in Enveric Biosciences in Q2 2026 and has held it in 2 quarters since.
10 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.